A phase 1b study of humanized KS-interleukin-2 (huKS-IL2) immunocytokine with cyclophosphamide in patients with EpCAM-positive advanced solid tumors

Correlation of immune responses with survival in a randomized phase II study investigating multipeptide vaccination with IMA901 plus or minus low-dose cyclophosphamide in advanced renal cell carcinoma (RCC).

(2017) H. Singh et al.   JOURNAL OF CLINICAL ONCOLOGY

Epithelial cell adhesion molecule expression (CD326) in cancer: A short review

(2011) Carlo Patriarca et al.   CANCER TREATMENT REVIEWS

Clinical Cancer Therapy by NK Cells via Antibody-Dependent Cell-Mediated Cytotoxicity

(2011) Kory L. Alderson et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody

(2010) Christine E. Richter et al.   AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY

EpCAM in carcinogenesis: the good, the bad or the ugly

(2010) B. T. F. van der Gun et al.   CARCINOGENESIS

Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma

(2009) Alexei V. Salnikov et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanoma

(2009) Antoni Ribas et al.   Journal of Translational Medicine

Low-Dose Cyclophosphamide and Continuous-Infusion Interleukin-2 with Famotidine in Previously Treated Metastatic Melanoma or Kidney Cancer

(2008) Walter D.Y. Quan et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Intratumoral immunocytokine treatment results in enhanced antitumor effects

(2008) Erik E. Johnson et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY